tiprankstipranks
Trending News
More News >
Abbvie (GB:0QCV)
:0QCV
UK Market
Advertisement

AbbVie (0QCV) Share Forecast & Price Target

Compare
11 Followers
See the Price Targets and Ratings of:

0QCV Analyst Ratings

Moderate Buy
22Ratings
Moderate Buy
15 Buy
7 Hold
0 Sell
Based on 22 analysts giving stock ratings to
AbbVie
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0QCV Stock 12 Month Forecast

Average Price Target

$242.16
▲(6.62% Upside)
Based on 22 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is $242.16 with a high forecast of $284.00 and a low forecast of $203.00. The average price target represents a 6.62% change from the last price of $227.12.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"170":"$170","285":"$285","198.75":"$198.8","227.5":"$227.5","256.25":"$256.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":284,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$284.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":242.16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$242.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":203,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$203.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[170,198.75,227.5,256.25,285],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,240.912,244.22646153846154,247.5409230769231,250.85538461538462,254.16984615384615,257.4843076923077,260.7987692307692,264.11323076923077,267.4276923076923,270.7421538461538,274.0566153846154,277.37107692307694,280.68553846153844,{"y":284,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,240.912,241.008,241.104,241.20000000000002,241.296,241.392,241.488,241.584,241.68,241.776,241.87199999999999,241.968,242.064,{"y":242.16,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,240.912,237.9956923076923,235.0793846153846,232.16307692307691,229.24676923076925,226.33046153846155,223.41415384615385,220.49784615384615,217.58153846153846,214.66523076923076,211.74892307692306,208.8326153846154,205.9163076923077,{"y":203,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":188.751,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":197.651,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.523,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":171.233,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":180.221,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":200.458,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.304,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.362,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.289,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":187.13,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":194.217,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":208.586,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":240.912,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$284.00Average Price Target$242.16Lowest Price Target$203.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on GB:0QCV
Piper Sandler
Piper Sandler
$284
Buy
25.04%
Upside
Reiterated
10/28/25
Piper Sandler Sticks to Its Buy Rating for AbbVie (ABBV)
Berenberg Bank Analyst forecast on GB:0QCV
Berenberg Bank
Berenberg Bank
$270
Buy
18.88%
Upside
Reiterated
10/27/25
AbbVie (ABBV) Receives a Buy from Berenberg Bank
Goldman Sachs Analyst forecast on GB:0QCV
Goldman Sachs
Goldman Sachs
$217$218
Hold
-4.02%
Downside
Reiterated
10/23/25
AbbVie Hold Rating: Balancing Strong Performance with Emerging Challenges
TR | OpenAI - 4o Analyst forecast on GB:0QCV
TR | OpenAI - 4o
TR | OpenAI - 4o
$228$248
Hold
9.19%
Upside
Reiterated
10/22/25
AI Generated ArticleAI Generated Article
Bernstein
$203
Hold
-10.62%
Downside
Assigned
10/21/25
Bernstein Sticks to Its Hold Rating for AbbVie (ABBV)
Bank of America Securities Analyst forecast on GB:0QCV
Bank of America Securities
Bank of America Securities
$251
Hold
10.51%
Upside
Reiterated
10/20/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (NYSE: ABBV), Alpha Cognition Inc (NASDAQ: ACOG) and Exelixis (NASDAQ: EXEL)
Guggenheim Analyst forecast on GB:0QCV
Guggenheim
Guggenheim
$227$242
Buy
6.55%
Upside
Reiterated
10/19/25
Guggenheim Sticks to Their Buy Rating for AbbVie (ABBV)
Raymond James Analyst forecast on GB:0QCV
Raymond James
Raymond James
$236$250
Buy
10.07%
Upside
Reiterated
10/17/25
AbbVie price target raised to $250 from $236 at Raymond JamesAbbVie price target raised to $250 from $236 at Raymond James
Wells Fargo Analyst forecast on GB:0QCV
Wells Fargo
Wells Fargo
$260
Buy
14.48%
Upside
Reiterated
10/14/25
Wells Fargo Sticks to Their Buy Rating for AbbVie (ABBV)
Citi
Hold
Reiterated
10/14/25
Citi Sticks to Their Hold Rating for AbbVie (ABBV)
Cantor Fitzgerald Analyst forecast on GB:0QCV
Cantor Fitzgerald
Cantor Fitzgerald
$250
Buy
10.07%
Upside
Reiterated
10/14/25
Cantor Fitzgerald Sticks to Its Buy Rating for AbbVie (ABBV)
Leerink Partners Analyst forecast on GB:0QCV
Leerink Partners
Leerink Partners
$243
Buy
6.99%
Upside
Reiterated
10/14/25
Leerink Partners Keeps Their Buy Rating on AbbVie (ABBV)
Erste Group Analyst forecast on GB:0QCV
Erste Group
Erste Group
Hold
Downgraded
10/13/25
AbbVie downgraded to Hold from Buy at Erste GroupAbbVie downgraded to Hold from Buy at Erste Group
J.P. Morgan Analyst forecast on GB:0QCV
J.P. Morgan
J.P. Morgan
$235$250
Buy
10.07%
Upside
Reiterated
10/09/25
Analysts Offer Insights on Healthcare Companies: Compugen (NASDAQ: CGEN) and AbbVie (NYSE: ABBV)
HSBC
$210$225
Hold
-0.93%
Downside
Downgraded
10/01/25
AbbVie downgraded to Hold from Buy at HSBCAbbVie downgraded to Hold from Buy at HSBC
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on GB:0QCV
Piper Sandler
Piper Sandler
$284
Buy
25.04%
Upside
Reiterated
10/28/25
Piper Sandler Sticks to Its Buy Rating for AbbVie (ABBV)
Berenberg Bank Analyst forecast on GB:0QCV
Berenberg Bank
Berenberg Bank
$270
Buy
18.88%
Upside
Reiterated
10/27/25
AbbVie (ABBV) Receives a Buy from Berenberg Bank
Goldman Sachs Analyst forecast on GB:0QCV
Goldman Sachs
Goldman Sachs
$217$218
Hold
-4.02%
Downside
Reiterated
10/23/25
AbbVie Hold Rating: Balancing Strong Performance with Emerging Challenges
TR | OpenAI - 4o Analyst forecast on GB:0QCV
TR | OpenAI - 4o
TR | OpenAI - 4o
$228$248
Hold
9.19%
Upside
Reiterated
10/22/25
AI Generated ArticleAI Generated Article
Bernstein
$203
Hold
-10.62%
Downside
Assigned
10/21/25
Bernstein Sticks to Its Hold Rating for AbbVie (ABBV)
Bank of America Securities Analyst forecast on GB:0QCV
Bank of America Securities
Bank of America Securities
$251
Hold
10.51%
Upside
Reiterated
10/20/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (NYSE: ABBV), Alpha Cognition Inc (NASDAQ: ACOG) and Exelixis (NASDAQ: EXEL)
Guggenheim Analyst forecast on GB:0QCV
Guggenheim
Guggenheim
$227$242
Buy
6.55%
Upside
Reiterated
10/19/25
Guggenheim Sticks to Their Buy Rating for AbbVie (ABBV)
Raymond James Analyst forecast on GB:0QCV
Raymond James
Raymond James
$236$250
Buy
10.07%
Upside
Reiterated
10/17/25
AbbVie price target raised to $250 from $236 at Raymond JamesAbbVie price target raised to $250 from $236 at Raymond James
Wells Fargo Analyst forecast on GB:0QCV
Wells Fargo
Wells Fargo
$260
Buy
14.48%
Upside
Reiterated
10/14/25
Wells Fargo Sticks to Their Buy Rating for AbbVie (ABBV)
Citi
Hold
Reiterated
10/14/25
Citi Sticks to Their Hold Rating for AbbVie (ABBV)
Cantor Fitzgerald Analyst forecast on GB:0QCV
Cantor Fitzgerald
Cantor Fitzgerald
$250
Buy
10.07%
Upside
Reiterated
10/14/25
Cantor Fitzgerald Sticks to Its Buy Rating for AbbVie (ABBV)
Leerink Partners Analyst forecast on GB:0QCV
Leerink Partners
Leerink Partners
$243
Buy
6.99%
Upside
Reiterated
10/14/25
Leerink Partners Keeps Their Buy Rating on AbbVie (ABBV)
Erste Group Analyst forecast on GB:0QCV
Erste Group
Erste Group
Hold
Downgraded
10/13/25
AbbVie downgraded to Hold from Buy at Erste GroupAbbVie downgraded to Hold from Buy at Erste Group
J.P. Morgan Analyst forecast on GB:0QCV
J.P. Morgan
J.P. Morgan
$235$250
Buy
10.07%
Upside
Reiterated
10/09/25
Analysts Offer Insights on Healthcare Companies: Compugen (NASDAQ: CGEN) and AbbVie (NYSE: ABBV)
HSBC
$210$225
Hold
-0.93%
Downside
Downgraded
10/01/25
AbbVie downgraded to Hold from Buy at HSBCAbbVie downgraded to Hold from Buy at HSBC
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AbbVie

1 Month
xxx
Success Rate
12/15 ratings generated profit
80%
Average Return
+4.34%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +4.34% per trade.
3 Months
xxx
Success Rate
12/15 ratings generated profit
80%
Average Return
+9.47%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +9.47% per trade.
1 Year
Evan SeigermanBMO Capital
Success Rate
17/17 ratings generated profit
100%
Average Return
+21.45%
reiterated a buy rating 2 months ago
Copying Evan Seigerman's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +21.45% per trade.
2 Years
xxx
Success Rate
15/15 ratings generated profit
100%
Average Return
+39.91%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +39.91% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0QCV Analyst Recommendation Trends

Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
0
0
0
0
0
Buy
27
25
34
40
33
Hold
21
24
20
17
13
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
48
49
54
57
46
In the current month, 0QCV has received 33 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. 0QCV average Analyst price target in the past 3 months is 242.16.
Each month's total comprises the sum of three months' worth of ratings.

0QCV Financial Forecast

0QCV Earnings Forecast

Next quarter’s earnings estimate for 0QCV is $1.77 with a range of $1.67 to $1.88. The previous quarter’s EPS was $2.97. 0QCV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year 0QCV has Preformed in-line its overall industry.
Next quarter’s earnings estimate for 0QCV is $1.77 with a range of $1.67 to $1.88. The previous quarter’s EPS was $2.97. 0QCV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year 0QCV has Preformed in-line its overall industry.

0QCV Sales Forecast

Next quarter’s sales forecast for 0QCV is $15.59B with a range of $15.38B to $15.88B. The previous quarter’s sales results were $15.42B. 0QCV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 0QCV has Preformed in-line its overall industry.
Next quarter’s sales forecast for 0QCV is $15.59B with a range of $15.38B to $15.88B. The previous quarter’s sales results were $15.42B. 0QCV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 0QCV has Preformed in-line its overall industry.

0QCV Stock Forecast FAQ

What is GB:0QCV’s average 12-month price target, according to analysts?
Based on analyst ratings, Abbvie’s 12-month average price target is 242.16.
    What is GB:0QCV’s upside potential, based on the analysts’ average price target?
    Abbvie has 6.62% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Abbvie a Buy, Sell or Hold?
          Abbvie has a consensus rating of Moderate Buy, which is based on 15 buy ratings, 7 hold ratings and 0 sell ratings.
            What is Abbvie’s share price target?
            The average share price target for Abbvie is 242.16. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $284.00 ,and the lowest forecast is $203.00. The average share price target represents 6.62% Increase from the current price of $227.12.
              What do analysts say about Abbvie?
              Abbvie’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.
                How can I buy shares of Abbvie?
                To buy shares of GB:0QCV, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis